FDA approves additional doses of Trulicity to treat type 2 diabetes

By NS Healthcare Staff Writer

04 Sep 20

AWARD-11 showed 3.0 mg and 4.5 mg doses led to additional blood sugar control; as a secondary endpoint,…

PharmaceuticalsRegulation

FDA approves Bristol Myers’ Onureg as continued treatment for AML

By NS Healthcare Staff Writer

02 Sep 20

The FDA approval is based on results from the Phase 3 QUAZAR AML-001 clinical trial, an international, randomised,…

PharmaceuticalsRegulation

Gilead gets expanded FDA EUA for Veklury to treat moderate Covid-19

By NS Healthcare Staff Writer

31 Aug 20

The EUA expands Veklury’s previous authorisation to treat hospitalised patients with Covid-19 regardless of oxygen status

PharmaceuticalsRegulation

GSK secures EC approval for BLENREP to treat multiple myeloma

By NS Healthcare Staff Writer

27 Aug 20

The EC regulatory approval for BLENREP is supported by data from the pivotal DRiving Excellence in Approaches to…

PharmaceuticalsRegulation

AstraZeneca’s Imfinzi approved to treat ES-SCLC in Japan

By NS Healthcare Staff Writer

24 Aug 20

Imfinzi is a human monoclonal antibody that targets and blocks the interaction of PD-L1 with PD-1 and CD80,…

PharmaceuticalsRegulation

AstraZeneca gets FDA priority review for Imfinzi for four-week fixed-dose use

By NS Healthcare Staff Writer

19 Aug 20

The US FDA accepted AstraZeneca’s supplemental Biologics License Application (sBLA) for Imfinzi, which is supported by data from…

PharmaceuticalsRegulation

CanSino Biologics’ Covid-19 vaccine granted patent approval in China

By NS Healthcare Staff Writer

18 Aug 20

CanSino's Ad5-nCoV will leverage an attenuated adenovirus vector to induce genetic material and activate the immune response in…

PharmaceuticalsRegulation

Genentech gets FDA approval for Enspryng to treat NMOSD

By NS Healthcare Staff Writer

17 Aug 20

The US FDA approval of Enspryng is based on results from two randomised controlled Phase 3 clinical trials,…

PharmaceuticalsRegulation

FDA accepts self-administration option for Xolair prefilled syringe

By NS Healthcare Staff Writer

14 Aug 20

Xolair is the only approved biologic to block immunoglobulin E (IgE), being jointly developed and co-promoted in the…

PharmaceuticalsRegulation

NS Pharma gets FDA approval for Viltepso injection to treat DMD

By NS Healthcare Staff Writer

13 Aug 20

The FDA has granted accelerated approval for Viltepso, based on its activity to boost dystrophin, a protein that…

PharmaceuticalsRegulation